Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
0QF Stock Chart & Stats
€20.58
-€2.54(-5.63%)
At close: 4:00 PM EST
€20.58
-€2.54(-5.63%)
Day’s Range― - ―
52-Week Range€19.89 - €49.27
Previous CloseN/A
Volume96.78K
Average Volume (3M)45.39K
Market Cap
$7.97B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.13B
Total Debt (Recent Filing)$686.00M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Feb 19, 2026EPS Estimate
-2.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding390,580,780
10 Day Avg. Volume65,202
30 Day Avg. Volume45,388
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.46
Price to Sales (P/S)4.99
P/FCF Ratio-3.94
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$34.75Price Target Upside68.87% Upside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost ManagementCost reduction, decreasing cash burn, and increasing efficiencies remain a focus for the company.
Oncology Pipeline ProgressThe prioritization of the company’s oncology assets is seen as having significant value, with potential Phase III adjuvant melanoma data potentiating quicker approval.
Vaccine Franchise RevenueMRNA's vaccine franchise could still produce approximately $1.0B annually through 2030.
Bears Say
CMV Vaccine Program SetbackThe Phase 3 pivotal study of mRNA-1647 (CMV vaccine) did not meet its primary efficacy endpoint of preventing CMV infection, leading to the discontinuation of congenital CMV development.
COVID-19 Vaccine SalesThe estimate for Q3 COVID-19 vaccine sales was reduced to $900MM from the prior $1.2B.
Revenue ChallengesRevenue needs to roughly double between now and 2028 to maintain breakeven guidance without radically changing the organization.
Moderna News
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €19.89 and its highest was €49.27 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $7.97B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Feb 19, 2026 which is in 103 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Nov 06, 2025. The company reported -€0.441 earnings per share for the quarter, beating the consensus estimate of -€1.621 by €1.18.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.31.
How many shares outstanding does Moderna have?
Moderna has 390,580,780 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€0.441 in its last earnings report, beating expectations of -€1.621. Following the earnings report the stock price went down -0.097%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in DE:0QF
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$34.75 (68.87% Upside)
$34.75 (68.87% Upside)
Blogger Sentiment
Bullish
DE:0QF Sentiment 73%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.03%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
-23.41%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
0QF Company Deck
0QF Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in cost reduction, strategic partnerships, and product approvals. However, these positives were tempered by notable challenges, including a significant revenue decline, a net loss for the quarter, and the discontinuation of the CMV vaccine program.View all DE:0QF earnings summaries0QF Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
0QF Stock 12 Month Forecast
Average Price Target
€34.75
▲(68.87% Upside)
Technical Analysis
Options Prices
Currently, No data available
---